FOLD News and Press, Amicus Therapeutics Inc. From 07/17/20

Amicus Therapeutics (NASDAQ: FOLD ) inks an agreement with Hayfin Capital Management for a $400M credit facility at 6.5% above LIBOR subject to a 1% floor. More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings  Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring Prior Term Loan Company Reiterates 2020 Galafold Revenue of $2...

( Pexels ) Of all the investable sectors and industries, one of the top-performing over the past few months is biotechnology. Since its March low (18 th ), the SPDR Biotech ETF ( XBI ) has risen about 75% as investors speculate on virus treatment and vaccine rumors. Understandably, many in...

Amicus Therapeutics ( FOLD ) is a commercial stage biopharma that is seeing huge sales growth of its one marketed product, Galafold, which treats Fabry disease. Sales of Galafold are expected to easily exceed $1 billion as are sales of Amicus' late-stage therapy for Pompe disease, AT-GAA. Desp...

What would you value a developing biotech with BLA submission just filed with the FDA? In this case, a BLA filed for a drug with the potential to outcompete a Sanofi ( SNY ) near-blockbuster, and the company is flush with cash after closing a $44M private placement. Somewhere near all-time l...

CRANBURY, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 41 st Annual Global Healthcare Conference, being held virtually on Wedne...

Image source: The Motley Fool. Amicus Therapeutics Inc   (NASDAQ: FOLD) Q1 2020 Earnings Call May 9, 2020 , 8:30 p.m. ET Operator Continue reading

CRANBURY, N.J., May 08, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that its 2020 Annual Meeting of Stockholders will n...

Amicus Therapeutics, Inc. (FOLD) Q1 2020 Earnings Conference Call May 7, 2020 8:30 AM ET Company Participants Andrew Faughnan - Director of Investor Relations John Crowley - Chairman & Chief Executive Officer Bradley Campbell - President & Chief Operating Officer Daph...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...